

**WHI MANUALS**  
**VOLUME 1: STUDY PROTOCOL AND POLICIES**  
**TABLE OF CONTENTS AND INTRODUCTION**

---

**SECTION 1:     PROTOCOL FOR CLINICAL TRIAL AND OBSERVATIONAL STUDY COMPONENTS**

---

|           |                                                                      |             |
|-----------|----------------------------------------------------------------------|-------------|
| <b>1.</b> | <b>Summary.....</b>                                                  | <b>1-1</b>  |
| 1.1       | Summary of Clinical Trial.....                                       | 1-1         |
| 1.2       | Summary of Observational Study .....                                 | 1-1         |
| <b>2.</b> | <b>Background.....</b>                                               | <b>1-2</b>  |
| 2.1       | General Considerations .....                                         | 1-2         |
| 2.2       | Hormone Replacement Therapy.....                                     | 1-3         |
| 2.2.1     | Hormone Replacement Therapy and Coronary Heart Disease.....          | 1-3         |
| 2.2.2     | Hormone Replacement Therapy and Fractures .....                      | 1-4         |
| 2.2.3     | Potential Adverse Effects of Hormone Replacement Therapy.....        | 1-5         |
| 2.2.4     | The Need for a Controlled Trial of Hormone Replacement Therapy ..... | 1-6         |
| 2.3       | Dietary Modification.....                                            | 1-7         |
| 2.3.1     | Dietary Modification and Breast Cancer .....                         | 1-7         |
| 2.3.2     | Dietary Modification and Colorectal Cancer.....                      | 1-8         |
| 2.3.3     | Dietary Modification and Coronary Heart Disease.....                 | 1-9         |
| 2.3.4     | The Need for a Controlled Trial of a Low-Fat Eating Pattern .....    | 1-9         |
| 2.4       | Calcium and Vitamin D (CaD) Supplementation .....                    | 1-10        |
| 2.4.1     | Calcium, Vitamin D and Fractures .....                               | 1-10        |
| 2.4.2     | Calcium and Colorectal Cancer.....                                   | 1-11        |
| 2.4.3     | The Need for a Controlled Trial of CaD .....                         | 1-11        |
| 2.5       | Observational Study .....                                            | 1-11        |
| 2.5.1     | Observational Study Potential .....                                  | 1-11        |
| 2.5.2     | Need for the Observational Study .....                               | 1-13        |
| <b>3.</b> | <b>Study Objectives .....</b>                                        | <b>1-14</b> |
| 3.1       | Objectives of the Clinical Trial .....                               | 1-14        |
| 3.2       | Objectives of the Observational Study.....                           | 1-15        |
| <b>4.</b> | <b>Study Design .....</b>                                            | <b>1-17</b> |
| 4.1       | Overview.....                                                        | 1-17        |
| 4.2       | Choice of Treatments.....                                            | 1-18        |
| 4.2.1     | Hormones .....                                                       | 1-18        |
| 4.2.2     | Dietary Modification Component Goals .....                           | 1-19        |
| 4.2.3     | Dose and Preparation of CaD.....                                     | 1-21        |
| 4.2.4     | Exercise Advice .....                                                | 1-22        |
| 4.3       | Outcomes of Interest .....                                           | 1-22        |
| 4.3.1     | Major Clinical Outcomes .....                                        | 1-22        |
| 4.3.2     | Intermediate Outcomes .....                                          | 1-24        |
| 4.4       | Study Population.....                                                | 1-24        |
| 4.5       | Sample Size and Duration.....                                        | 1-28        |
| 4.6       | Informed Consent.....                                                | 1-28        |
| 4.7       | Randomization Assignment Blinding.....                               | 1-29        |
| 4.7.1     | Hormone Replacement Therapy.....                                     | 1-29        |
| 4.7.2     | Dietary Modification.....                                            | 1-30        |
| 4.7.3     | Calcium/Vitamin D.....                                               | 1-30        |
| 4.7.4     | Coordinating Center Blinding.....                                    | 1-30        |

|            |                                                                      |             |
|------------|----------------------------------------------------------------------|-------------|
| <b>5.</b>  | <b>Study Plan.....</b>                                               | <b>1-31</b> |
| 5.1        | General.....                                                         | 1-31        |
| 5.2        | Enrollment.....                                                      | 1-31        |
| 5.2.1      | General Screening.....                                               | 1-31        |
| 5.2.2      | Pre-Screening.....                                                   | 1-31        |
| 5.2.3      | First Screening Visit (SV1).....                                     | 1-34        |
| 5.2.4      | Second Screening Visit (SV2).....                                    | 1-35        |
| 5.2.5      | Third Screening Visit (SV3).....                                     | 1-36        |
| 5.2.6      | Study Registration and Randomization .....                           | 1-37        |
| 5.3        | Follow-Up.....                                                       | 1-38        |
| 5.3.1      | Clinical Trial.....                                                  | 1-38        |
| 5.3.2      | Observational Study.....                                             | 1-40        |
| 5.3.3      | Study Close-out.....                                                 | 1-40        |
| 5.4        | Adherence and Retention.....                                         | 1-42        |
| 5.5        | Evaluation and Management of Adverse Experiences in the CT .....     | 1-43        |
| 5.5.1      | Adverse Experience Monitoring.....                                   | 1-43        |
| 5.5.2      | HRT .....                                                            | 1-43        |
|            | General.....                                                         | 1-43        |
|            | Endometrial Evaluation.....                                          | 1-43        |
|            | Management of Vaginal Bleeding.....                                  | 1-44        |
|            | Discontinuation of HRT Treatment.....                                | 1-44        |
|            | Changing the HRT Arm.....                                            | 1-44        |
| 5.5.3      | Dietary Modification Component.....                                  | 1-45        |
| 5.5.4      | Calcium/Vitamin D Component .....                                    | 1-45        |
| 5.5.5      | Notifications.....                                                   | 1-45        |
|            | Immediate and Urgent Referrals .....                                 | 1-45        |
|            | Routine Referrals.....                                               | 1-47        |
| <b>6.</b>  | <b>Centralized Study Operations.....</b>                             | <b>1-48</b> |
| 6.1        | Data Management.....                                                 | 1-48        |
| 6.2        | Quality Assurance .....                                              | 1-48        |
| 6.3        | Drug Distribution .....                                              | 1-48        |
| 6.4        | Outcome Adjudication .....                                           | 1-48        |
| <b>7.</b>  | <b>Study Monitoring and Data Analysis .....</b>                      | <b>1-50</b> |
| 7.1        | General.....                                                         | 1-50        |
| 7.2        | Accrual, Adherence and Accumulated Outcome Events .....              | 1-50        |
| 7.3        | Monitoring of Clinical Events by Randomization Group in the CT ..... | 1-50        |
| 7.4        | Data Analysis .....                                                  | 1-51        |
| <b>8.</b>  | <b>Osteoporosis Substudy.....</b>                                    | <b>1-54</b> |
| <b>9.</b>  | <b>Ancillary Studies.....</b>                                        | <b>1-55</b> |
| <b>10.</b> | <b>Study Organization.....</b>                                       | <b>1-56</b> |
| <b>11.</b> | <b>Timetable.....</b>                                                | <b>1-59</b> |

## Figures

|    |                                                                                               |      |
|----|-----------------------------------------------------------------------------------------------|------|
| 1. | WHI CT Partial Factorial Design.....                                                          | 1-18 |
| 2. | WHI's Model Enrollment Activities and Flow: Pre-screening Through First Screening Visit ..... | 1-33 |
| 3. | WHI's Model Enrollment Activities and Flow: Second and Third Screening Visits .....           | 1-35 |
| 4. | Organization of the Study .....                                                               | 1-56 |

## Tables

|    |                                                                                                    |      |
|----|----------------------------------------------------------------------------------------------------|------|
| 1. | Fat Gram Goals for DM Component Based on Height.....                                               | 1-20 |
| 2. | Outcomes for WHI CT and OS.....                                                                    | 1-24 |
| 3. | OS - Estimates of Cumulative Number of Events For 100,000 Women Age 50-79 at Screening Visit ..... | 1-28 |

## Appendices

See Sections 1-A1 through 1-A9 for Protocol Appendices.

---

### SECTION 1-A1: PROTOCOL APPENDIX 1 - BASELINE AND FOLLOW-UP VARIABLES

---

|        |                              |        |
|--------|------------------------------|--------|
| 1-A1.1 | Variables.....               | 1-A1-1 |
| 1-A1.2 | Frequency of Collection..... | 1-A1-4 |

#### Tables

|        |                                    |        |
|--------|------------------------------------|--------|
| 1-A1.1 | Frequency of Data Collection ..... | 1-A1-5 |
|--------|------------------------------------|--------|

---

### SECTION 1-A2: PROTOCOL APPENDIX 2 - OVERVIEW OF CLASSIFICATION PROCEDURES AND DEFINITIONS OF CLINICAL OUTCOMES

---

**This Appendix has been deleted in its entirety. Outcomes will be addressed in  
Volume 8 of the WHI Manuals.**

---

### SECTION 1-A3: PROTOCOL APPENDIX 3 - STATISTICAL POWER FOR WHI CLINICAL TRIAL AND OBSERVATIONAL STUDY

---

|        |                          |         |
|--------|--------------------------|---------|
| 1-A3.1 | Clinical Trial (CT)..... | 1-A3-1  |
| 1-A3.2 | Observational Study..... | 1-A3-12 |

#### Tables

|        |                                                            |         |
|--------|------------------------------------------------------------|---------|
| 1-A3.1 | OS Power Calculations for Cohort Size of 100,000 .....     | 1-A3-16 |
| 1-A3.2 | OS Power Calculations for a Subsample Size of 80,000 ..... | 1-A3-17 |
| 1-A3.3 | OS Power Calculations for a Subsample Size of 40,000 ..... | 1-A3-18 |
| 1-A3.4 | OS Power Calculations for a Subsample Size of 20,000 ..... | 1-A3-19 |
| 1-A3.5 | OS Power Calculations for a Subsample Size of 10,000 ..... | 1-A3-20 |
| 1-A3.6 | OS Power Calculations for a Subsample Size of 6,000.....   | 1-A3-21 |
| 1-A3.7 | OS Power Calculations for a Subsample Size of 2,000.....   | 1-A3-22 |

---

**SECTION 1-A4:      PROTOCOL APPENDIX 4 - INFORMED CONSENT GUIDELINES**


---

THE CONSENT FORMS PREVIOUSLY FOUND IN SECTION 2-A4, PROTOCOL APPENDIX 4 WERE MOVED TO SECTION 2 OF VOLUME 1.

---

**SECTION 1-A5:      PROTOCOL APPENDIX 5 - WHI OBSERVATIONAL STUDY OVERVIEW OF OBJECTIVES AND HYPOTHESES**


---

1-A5.1 Objectives.....1-A5-1

1-A5.2 Hypotheses .....1-A5-1

**Tables**

1-A5.1 Cumulative Number of Events For 100,000 Women Age 50-79 Years At Baseline.....1-A5-7

1-A5.2 Summary of Exposure/Disease Hypotheses.....1-A5-7

1-A5.3 Biomarker Hypotheses and Plasma/Serum Volume Required.....1-A5-8

---

**SECTION 1-A6:      PROTOCOL APPENDIX 6 - DIETARY INTERVENTION PROGRAM AND DIETARY ASSESSMENT METHODS**


---

1-A6.1 Dietary Intervention Program.....1-A6-1

1-A6.2 Dietary Assessment Methods.....1-A6-7

**Tables**

1-A6.1 Summary of DM Intervention Sessions.....1-A6-4

1-A6.2 Nutrients Calculated from Nutrition Data System Database .....1-A6-8

---

**SECTION 1-A7:      PROTOCOL APPENDIX 7 - WHI STUDY UNITS AND PRINCIPAL INVESTIGATORS**


---

1-A7.1 National Institutes of Health (NIH).....1-A7-1

1-A7.2 Clinical Coordinating Center (CCC).....1-A7-1

1-A7.3 Vanguard Clinical Centers (VCCs).....1-A7-2

|                                           |               |
|-------------------------------------------|---------------|
| <b>1-A7.4 Clinical Centers (CCs).....</b> | <b>1-A7-3</b> |
|-------------------------------------------|---------------|

---

**SECTION 1-A8:      PROTOCOL APPENDIX 8 - BRIEF PROTOCOL HISTORY**


---

|        |                                                |     |
|--------|------------------------------------------------|-----|
| 1-A8.1 | Protocol Version Dated June 28, 1993 .....     | 8-1 |
| 1-A8.2 | Protocol Version Dated September 1, 1994 ..... | 8-2 |
| 1-A8.3 | Protocol Version Dated April 3, 1995 .....     | 8-3 |
| 1-A8.4 | Protocol Version Dated March 15, 1996 .....    | 8-4 |
| 1-A8.5 | Protocol Version Dated April 1, 1997 .....     | 8-5 |
| 1-A8.6 | Protocol Version Dated April 1, 1998 .....     | 8-6 |
| 1-A8.7 | Protocol Version Dated April 1, 1999 .....     | 8-7 |
| 1-A8.8 | Protocol Version Dated April 1, 2000 .....     | 8-7 |

---

**SECTION 1-A9:      PROTOCOL APPENDIX 9 - BIBLIOGRAPHY**


---

|        |                                                                                               |         |
|--------|-----------------------------------------------------------------------------------------------|---------|
| 1-A9.1 | Hormone Replacement Therapy, Coronary Heart Disease and Cancer of the Breast and Uterus ..... | 1-A9-1  |
| 1-A9.2 | Low-Fat Dietary Pattern, Cancer of the Breast and Colon, and Coronary Heart Disease .....     | 1-A9-3  |
| 1-A9.3 | Calcium, Vitamin D, Osteoporosis and Cancer .....                                             | 1-A9-7  |
| 1-A9.4 | Study Methodology .....                                                                       | 1-A9-10 |

---

**SECTION 2:              CONSENT FORMS**


---

**Initial Consent to Take part in the Women's Health Initiative (WHI).....Initial**

**Consent Form for the Hormone Replacement Therapy Part of the Women's Health Initiative (WHI) Clinical Trial**

Hormone Replacement Therapy: Risks and Benefits (For Women Who Either Do or Do Not have A Uterus)..... HRT  
Hormone Replacement Therapy: Risks and Benefits (For Women Who Have a Uterus)..... HRT  
Hormone Replacement Therapy: Risks and Benefits (For Women Who Have Had a Hysterectomy)..... HRT

**Consent Form for the Dietary Part of the Women's Health Initiative (WHI) Clinical Trial.....Dietary**

**Consent Form for the Calcium/Vitamin D Part of the Women's Health Initiative (WHI) Clinical Trial..... Calcium**

**Consent Form for the Observational Study Part of the Women's Health Initiative (WHI).....OS**

---

**SECTION 3: STUDY POLICIES**


---

|                                                                                                                           |             |
|---------------------------------------------------------------------------------------------------------------------------|-------------|
| <b>INTRODUCTION .....</b>                                                                                                 | <b>3-1</b>  |
| <b>3.1 Study Documents .....</b>                                                                                          | <b>3-2</b>  |
| 3.1.1 Protocol: Purpose .....                                                                                             | 3-2         |
| 3.1.2 Changes to the Protocol.....                                                                                        | 3-2         |
| 3.1.3 WHI Manuals: Purpose.....                                                                                           | 3-2         |
| 3.1.4 Changes to the WHI Manuals .....                                                                                    | 3-2         |
| 3.1.5 WHI Manual Structure .....                                                                                          | 3-2         |
| <b>3.2 Publications and Presentations .....</b>                                                                           | <b>3-4</b>  |
| 3.2.1 Policy Objectives.....                                                                                              | 3-4         |
| 3.2.2 Definitions .....                                                                                                   | 3-4         |
| 3.2.3 Review of WHI Publications and Presentations .....                                                                  | 3-4         |
| 3.2.4 Authorship for Group-Authored and Individually-Authored Studywide Publications and Presentations.....               | 3-5         |
| 3.2.5 Authorship for Other Publications and Presentations .....                                                           | 3-5         |
| 3.2.6 Clearance of Abstracts and Presentation of Reports .....                                                            | 3-6         |
| 3.2.7 Invitations to WHI for Presentation of Papers .....                                                                 | 3-6         |
| 3.2.8 Procedures for Identifying Studywide Publications .....                                                             | 3-7         |
| 3.2.9 Identification of Writing Committees, Selection of Writing Committee Chair,<br>and Work of Writing Committees ..... | 3-7         |
| 3.2.10 Reporting of Race and Ethnicity Data.....                                                                          | 3-9         |
| 3.2.11 Umbrella Grant and OS Blood Ancillary Study Publication Policy.....                                                | 3-10        |
| 3.2.12 Preparations and Submission of Abstracts.....                                                                      | 3-10        |
| 3.2.13 Preparation and Submission of Papers for Publication .....                                                         | 3-10a       |
| 3.2.14 Identification of Additional Papers .....                                                                          | 3-10a       |
| 3.2.15 Use of WHI Data for Theses by Graduate Students .....                                                              | 3-10a       |
| 3.2.16 Use of WHI Data for Grant Application or Contract Proposal.....                                                    | 3-10b       |
| 3.2.17 Policy for the WHI Distributed Baseline Data Set .....                                                             | 3-10b       |
| 3.2.18 Accepting Outside Funding for WHI Statistical Analyses .....                                                       | 3-10d       |
| 3.2.19 End of Study Clinical Trial Priority Papers .....                                                                  | 3-10e       |
| 3.2.20 Writing Group Appeals .....                                                                                        | 3-10f       |
| <b>3.3 Examples of Publication and Presentation Documents.....</b>                                                        | <b>3-11</b> |
| 3.3.1 WHI Publications and Presentations Committee Progress Report.....                                                   | 3-11        |
| 3.3.2 Example of Manuscript Proposal.....                                                                                 | 3-12        |
| Introduction .....                                                                                                        | 3-12        |
| Analysis Plan .....                                                                                                       | 3-12        |
| Conclusions .....                                                                                                         | 3-16        |
| References .....                                                                                                          | 3-17        |
| 3.3.3 "Letter of Intent" .....                                                                                            | 3-18        |
| 3.3.4 WHI Responsibilities of Writing Group Chair and Writing Group Members .....                                         | 3-19        |
| <b>3.4 Ancillary Studies.....</b>                                                                                         | <b>3-20</b> |
| 3.4.1 General Policy .....                                                                                                | 3-20        |
| 3.4.2 Definition .....                                                                                                    | 3-20        |
| 3.4.3 Approval Process.....                                                                                               | 3-21        |
| Approval to Submit an External Funding Request.....                                                                       | 3-21        |
| Use of Biological Specimens - Priorities for Blood Specimens.....                                                         | 3-22        |
| Recruitment and Consenting of WHI Participants to Ancillary Studies .....                                                 | 3-23        |
| Funding.....                                                                                                              | 3-23        |
| Approval to Initiate Ancillary Study.....                                                                                 | 3-23        |
| 3.4.4 Analysis and Data Ownership .....                                                                                   | 3-23        |

---

|            |                                                                            |             |
|------------|----------------------------------------------------------------------------|-------------|
|            | Ancillary Study Tracking .....                                             | 3-24        |
|            | Approval of Publications and Presentations .....                           | 3-24        |
| 3.4.5      | Umbrella Studies Publication Policy.....                                   | 3-24        |
| <b>3.5</b> | <b>Quality Assurance Site Visits .....</b>                                 | <b>3-25</b> |
| <b>3.6</b> | <b>Clinical Center Access to Local WHI Data.....</b>                       | <b>3-26</b> |
| <b>3.7</b> | <b>Policy for CC Modifications to the Local WHI Computing System .....</b> | <b>3-27</b> |
| <b>3.8</b> | <b>Participant Materials.....</b>                                          | <b>3-29</b> |
| 3.8.1      | Reviewing and Archiving CC Materials .....                                 | 3-29        |
|            | CC Submission of Materials .....                                           | 3-29        |
|            | IRB Approval.....                                                          | 3-29        |
|            | CCC Review for Accuracy and Readability.....                               | 3-29        |
|            | Approval of Study-Wide Materials.....                                      | 3-29        |
|            | Archiving at the CCC.....                                                  | 3-29        |
|            | Summary .....                                                              | 3-30        |
| <b>3.9</b> | <b>Access to Samples in WHI Blood Repository.....</b>                      | <b>3-31</b> |
| 3.9.1      | Introduction .....                                                         | 3-31        |
| 3.9.2      | Observational Study .....                                                  | 3-31        |
|            | Sampling Frame, Volumes, and Objective of Blood .....                      | 3-31        |
|            | Ancillary Studies .....                                                    | 3-33        |
|            | Umbrella Studies.....                                                      | 3-35        |
|            | Confidentiality .....                                                      | 3-36        |
|            | Informed Consent.....                                                      | 3-36        |
| 3.9.3      | Clinical Trial.....                                                        | 3-36        |
|            | Sampling Frame, Volumes, and Objective of Blood .....                      | 3-36        |
|            | Ancillary Studies .....                                                    | 3-38        |
|            | Confidentiality .....                                                      | 3-40        |
|            | Informed Consent.....                                                      | 3-40        |

## Figures

|     |                                 |      |
|-----|---------------------------------|------|
| 3.1 | Types of Clinic Materials ..... | 3-30 |
|-----|---------------------------------|------|

## Tables

|     |                                                                                                                     |      |
|-----|---------------------------------------------------------------------------------------------------------------------|------|
| 3.1 | Prevalence of Gray Matter and Ventricular Changes by Age .....                                                      | 3-14 |
| 3.2 | Prevalence of White Matter Changes by Age.....                                                                      | 3-14 |
| 3.3 | Prevalence of Gray Matter and Ventricular Changes by Clinical Disease,<br>Subclinical Disease and Risk Factors..... | 3-15 |
| 3.4 | Correlates (r) of Gray Matter and Ventricular Changes (Continuous Measures).....                                    | 3-16 |
| 3.5 | Independent Correlates of Gray Matter Changes Based on Significant Variables from Bivariate Analyses.....           | 3-16 |
| 3.6 | Independent Correlates of White Matter Changes Based on Significant Variables from Bivariate Analyses .....         | 3-16 |

---

## SECTION 4:

---

**Not included in Volume 1 of the Manual at time of second printing (June, 1995).**



---

**SECTION 5:**

---

**Not included in Volume 1 of the Manual at time of second printing (June, 1995).**

---

**SECTION 6:**

---

Not included in Volume 1 of the Manual at time of second printing (June, 1995).

---

---

**SECTION 7:**

---

Not included in Volume 1 of the Manual at time of second printing (June, 1995).

---

---

**SECTION 8:**

---

Not included in Volume 1 of the Manual at time of second printing (June, 1995).

---

---

**SECTION 9:**

---

Not included in Volume 1 of the Manual at time of second printing (June, 1995).

---

**APPENDIX A**

Summary of Bulletins in Vol. 1 .....Page A-1

**APPENDIX B**

Not included in Volume 1 of the Manual at time of second printing (June, 1995).

**APPENDIX C**

Not included in Volume 1 of the Manual at time of second printing (June, 1995).

**APPENDIX D**

Not included in Volume 1 of the Manual at time of second printing (June, 1995).

**APPENDIX E**

Not included in Volume 1 of the Manual at time of second printing (June, 1995).

**APPENDIX F**

Not included in Volume 1 of the Manual at time of second printing (June, 1995).

**APPENDIX G**

Not included in Volume 1 of the Manual at time of second printing (June, 1995).

## INTRODUCTION TO WOMEN'S HEALTH INITIATIVE: CLINICAL TRIALS AND OBSERVATIONAL STUDY

### INTRODUCTION

The health of women has extraordinary medical, social, and economic importance, as well as the personal interest of women in making choices of healthy behaviors. However, too little research has focused on health issues unique to, or more common for, women. This is especially the case for studies of chronic diseases in mature women. These conditions, cardiovascular disease, cancer, and osteoporosis, are the leading causes of mortality, morbidity, and declining quality of life. Recognizing this, in 1991 the Director of the National Institutes of Health (NIH) announced the development of a research program to address these issues. These studies have been titled the Women's Health Initiative (WHI). Scientific staff from 10 Institutes of NIH joined together to plan this program that is coordinated by the Office of Disease Prevention and the Office of Research on Women's Health.

### Purpose

The WHI is composed of three studies: a Clinical Trial (CT), an Observational Study (OS), and a community based study. For efficiency the CT and OS have been combined into one program. This manual describes the protocol for both of these studies and the study policies.

### WHI Manuals

The design and implementation of the WHI, as captured in the study Protocol, policies, procedures, interventions, and data collection instruments are described in the WHI Manuals. The primary function of these manuals is to provide common training and reference materials across all participating WHI organizations as a way of assuring the quality of the study. Each operational unit is responsible for developing its own manual describing the policies and procedures specific to that unit.

The WHI Manuals are contained in several volumes. The allocation of topics to volumes was based on the WHI staff members who would most use the various sections.

**Volume 1 - Study Protocol and Policies:** This manual contains the Protocol for the CT and OS, the committee structure and the policies governing the scientific conduct of the study. As this is a document written for and by WHI Investigators, procedural aspects of the study that are performed by Investigators (e.g., outcomes classification) are included in this manual.

**Volume 2 - Procedures:** This manual describes all Clinical Center (CC) procedures and guidelines for operations other than Nutrition Intervention. As the primary CC training and reference source, this manual serves as the standard by which CC operations are assessed.

**Volume 3 - Forms:** All standardized study forms are displayed in the Forms Manual in numerical order. Accompanying each form is a detailed set of instructions describing who completes the form, when and how each data item should be coded, and what should happen to the form when completed.

**Volume 4 - Dietary Modification Intervention:** The Dietary Modification (DM) Intervention Manual consists of two parts: the Group Nutritionist Manual and the Participant Manual. The Group Nutritionist Manual describes the procedures for carrying out the intervention sessions for the DM component. The Participant Manual contains information pertinent to each intervention session.

**Volume 5 - Data System:** This is a user's manual for the WHI computing system. Information is provided on the general hardware and software used as well as the specific WHI database, WHILMA.

**Volume 6 - DXA Quality Assurance Manual for Hologic QDR-2000 Bone Densitometer:** This is a user's manual for the WHI Bone Density CCs. This manual is intended as a supplement to the Hologic User's Manual.

**Volume 7 - Quality Assurance Manual:** This manual provides procedures and checklists for CC QA Activities.

**Volume 8 - Outcomes:** This manual provides procedures and forms for outcome ascertainment and adjudication.